Kornimate/medical-research-clean huggingface dataset:
evaluation of fetal cardiac function in rheumatic heart disease (rhd) patients

Conditions: Fetal Distress

Summary: the goal of this study is to evaluate fetal myocardial performance in patients with heart diseases in comparison to normal pregnant patients.

cardiac diseases affect 1-4% of pregnancies of industrialized countries,and the number of patients who develop cardiac problems during pregnancy is increasing. congenital heart diseases, ischemic heart and cardiac arrhythmias are the most dominant causes. in developing countries, rheumatic heart disease remains prevalent. pregnancy induces haemodynamic changes with increased intravascular volume which may not only poses a risk of maternal death but also of serious morbidity such as heart failure, stroke and cardiac arrhythmia. the fetus is not spared.previous reports revealed a significant reduction in fetal growth rates associated with maternal heart disease.there is also association with preterm delivery and reduced birth weight. the presence of maternal cyanosis and a reduced cardiac output are the most significant predictors. accurate and reliable measurement of fetal cardiac function could be valuable for making the diagnosis and for fetal surveillancethe most suitable parameters for assessing fetal cardiac function will mainly be determined by the cause of the dysfunction. abnormal values of ejection fraction or cardiac output are usually found in the late stages of deterioration, and therefore more sensitive parameters have been proposed for earlier diagnosis and monitoring of fetal cardiac dysfunction. in most cases of cardiac dysfunction, diastolic parameters (such as dv or irt) are the first to be altered, reflecting impaired relaxation and compliance due to a stiffer or less effective heart. similarly, parameters reflecting longitudinal function (such as annular displacement or velocities) are typically affected in the early stages as compared to radial function (such as ejection fraction). the goal of this study is to evaluate fetal myocardial performance in patients with heart diseases in comparison to normal pregnant patients.

Eligibility criteria:
inclusion criteria: 1. compensated heart disease. 2. singleton pregnancy 3. normal placental location 4. have no associated hypertension, diabetes or any other medical disorders affecting pregnancy exclusion criteria: the patients have hypertension, diabetes or any other medical disorders affecting pregnancy.
omega-3 supplementation for tetraplegics with poor cholesterol levels

Conditions: Spinal Cord Injury; Tetraplegia; Quadraplegia; Low HDL-c; High LDL-c

Summary: people with a spinal cord injury (sci) characteristically have low levels of high-density lipoprotein-cholesterol (hdl-c; "good cholesterol") and high levels of low-density lipoprotein-cholesterol (ldl-c; "bad cholesterol"), and are at a higher risk of developing cardiovascular health problems, such as heart disease, heart attack and stroke, than the able-bodied population. a common way for able-bodied people to improve their lipid profile is through exercise; however, sci people, especially tetraplegics, are often unable to achieve and maintain a level of exercise needed to obtain these benefits. it is therefore clinically important to find an effective, safe and inexpensive method of increasing hdl-c levels in people with chronic tetraplegia. this study will investigate the effects of omega-3 fatty acid supplementation on the lipid profile of people with tetraplegia. the investigators hypothesize that 5 months of daily consumption of high doses of omega-3 fatty acids will increase plasma levels of hdl-c in those with tetraplegia, leading to decreased risk of cardiovascular health issues.


Eligibility criteria:
inclusion criteria: * having chronic tetraplegia (at least on year since injury) * 18 years or older * having below normal fasting blood plasma levels of hdl-c (\<1 mmol/l) exclusion criteria: * currently taking omega-3 supplements * currently taking medications for abnormal cholesterol * having a heart attack or stroke in the past one year

Keywords: spinal cord injury tetraplegia quadraplegia cholesterol hdl-c ldl-c omega-3 fatty acids
therapeutic exercise to treat neuropathic pain

Conditions: Gaucher Disease; Fabry Disease

Summary: a quasi-experimental, prospective clinical trial with pre and post intervention measurements, whose porpuose is assess the efficacy of a therapeutic exercise protocol to treat neuropathic pain in fabry disease.

there take part in this study women or men aged between 18 and 65 years, with a diagnosys by a physician specializing in fabry disease with fabryscan. patients must present a stable evolution, with a scoring system of disease severity (ds3) that must be less than 8 points per year in the last 2-3 years and they have to presence of neuropathic pain with a score greater than or equal to 4 in the questionnaire "douleur neuropathique (dn4)".

Eligibility criteria:
inclusion criteria: * female or male patients between 18 years and 65 years. * patients diagnosed by a doctor specializing in fabry disease with fabryscan. * fabry's disease must have a stable evolution, with a disease severity scoring system (ds3) that must be less than 8 points per year in the last 2-3 years. * presence of neuropathic pain with a score greater than or equal to 4 in the "douleur neuropathique (dn4)" questionnaire. exclusion criteria: * patients with an acute cardiovascular disease or with a heart or kidney transplant. * subjects with acute orthopedic problems that limit their participation in the study. * subjects with cognitive impairments that prevent them from filling in the questionnaires or understanding the exercises to be performed.

Keywords: gaucher disease exercise terapheutic
intramedullary resorbable fixation system versus k-wire for the treatment of lesser toe deformities

Conditions: Hammer Toe; Surgery; Deformity of Toe; Phalanx; Dislocation Toe(S)

Summary: hammertoe deformity is one of the most common deformities in the foot and is characterized by dorsiflexion of the proximal phalanx at the metatarsal-phalangeal joint and a plantarflexion of the middle phalanx at the proximal interphalangeal joint. surgical intervention for this type of deformity is indicated when the symptoms progress and conservative treatments are not enough, that is, when we are faced with a rigid painful deformity.arthrodesis of the proximal interphalangeal joint temporarily fixed with a kirschner wire is the most commonly used techniques. therefore, intramedullary fixation with a plla needle may be a good alternative. the use of biomaterial is gaining relevance in foot surgery, with polylactic acid being the most widely used due to its strength. its total biodegradation requires a time of 16-24 months. no cases of foreign body reaction have been described with this type of osteosynthesis material, due to its characteristics similar to those of bone. its only drawbacks are that it increases the complexity of the technique and that it increases the cost of the procedure. being a flexible needle, it allows to leave a functional intraoperative claw. it maintains the functionality of the distal interphalangeal joint and carries a lower risk of infection by carrying osteosynthesis material on the outside. the purpose of the present study is to prospectively collect clinical and radiographic outcomes of operative correction of hammertoe deformity using a fixation system of intramedullary device of polylactic acid versus a kirschner wire.

a comparative, prospective, randomised study.

Eligibility criteria:
inclusion criteria: * clinical and radiological evidence of rigid hammer toe. * non-smoking patient. * have no previous surgical episode or known trauma to the foot or ankle of the same limb. * not have any significant medical comorbidity: * uncontrolled hypertension. * previous myocardial infarction. * neoplasms. * chronic obstructive pulmonary disease. * arrhythmias. * morbid obesity. * uncontrolled diabetes mellitus. * peripheral vascular disease. * peripheral neuropathy. * lumbar disc herniation. * any neuro-muscular alteration. * that the patient present: * palpable peripheral pulses through the posterior tibial artery and pedia. * ankle-brachial index or yao between 1-1.2. * partial oxygen saturation\> or = 95%. exclusion criteria: * that the patient has undergone another previous surgical procedure on the same foot. * known trauma to the foot to be intervened. * history of sensitivity to local anesthetics. * pregnant or lactating women. * follow-up time less than 90 days. * patients with any systemic pathology or in chronic treatment that could interfere with the favorable evolution of the process.

Keywords: arthodesis kirschner wire plla
older person's exercise and nutrition study

Conditions: Mobility Limitations; Malnutrition

Summary: the novelty with the open study is to evaluate the effects of the simple sit-to-stand exercise during routine care, in combination with an oral protein-rich supplement, on functional status and independence in frail older persons. in this study we will also explore the experiences among older persons in the intervention group as wells as among staff of promoting the sit-to-stand exercise and nutritional supplement to gain knowledge for implementation as a daily routine in nursing homes across sweden. hypothesis the main hypothesis of the open study is that physical exercise performed as a daily routine along with an oral protein-rich supplement, will result in improved functional status and independence in everyday life activities and thereby enhance health-related quality of life in older persons living in nursing homes. the primary outcome measure for functional status will be the number of sit-to-stands that the participant is able to complete in 30 seconds. specific aims aim i: to study the effects of the sit-to-stand exercise combined with an oral protein-rich supplement on functional and nutritional status, and health-related quality of life, and the frequency and incidence of falls, pressure ulcers and incontinence in older persons living in nursing homes. furthermore, the cost effectiveness of the combination of the sit to stand exercise and oral protein-rich supplement vs. the control group will also be examined. aim ii: to describe the older persons' perceptions of daily being offered to conduct the sit-to-stand exercise and to drink the nutritional supplement. aim iii: to describe staff's perceptions of supporting the sit-to-stand exercise and the nutritional supplement with older persons living in nursing homes.


Eligibility criteria:
inclusion criteria: * able to rise independently from a seated position to standing- exclusion criteria: * bmi \>30 * severe dysphagia, * tube feeding, * severe kidney failure, * bedridden people, * terminal stage of life * lack of informed consent.
novel candidate genes for treatment response to antipsychotics in schizophrenia

Conditions: Schizophrenia

Summary: schizophrenia is a severe and chronic mental disorder. the lifetime risk of schizophrenia is around 1%. its course is chronic and frequently disabling. the keystone of schizophrenia treatment is antipsychotic medications. the use of antipsychotics represents a huge public health and economic burden to society. most of antipsychotics drugs are "metoo" drugs, directly or indirectly replicating dopamine d2 receptor blockade. pharmaceutical companies have aimed to produce drugs with a general indication for all patients with schizophrenia with a "one-size-fits-all" strategy with no targeting or stratification. second generation antipsychotics partly improve positive symptoms and are quite often associated to weight gain, metabolic changes and increased risk of cardiovascular diseases. antipsychotics only achieve a certain degree of clinical improvement in a percentage of patients (45%) and 30% of the patients are treatment resistant. in light of the current deadlock, there is an urgent need to expand the horizon of pharmacological research by elucidating new mechanisms related to antipsychotic actions. an alternative strategy is the comparison of gene expression profiles in drug-naive accurately ill patients before and after antipsychotic treatment has been initiated. our research group has a great experience in the field and has been working on this hypothesis in the latest years. we propose a continuation project to thoroughly explore the clinical implications (clinical response to antipsychotic drugs or emergence of metabolic side effects) of the variants in gene expression we have recently described in schizophrenia patients. this project takes advantage of an exceptional (regarding to the detailed knowledge of clinical outcome and side effect profile) longitudinal cohort of drug-naive patients with schizophrenia who had been followed up for three years at the university hospital marqués de valdecilla.


Eligibility criteria:
inclusion criteria: * patients followed up for 3 years in the first episode psychosis clinical program (pafip). * 15-60 years. * living in the catchment area. * experiencing their first episode of psychosis. * no prior treatment with antipsychotic medication or, if previously treated, a total life time of adequate antipsychotic treatment of less than 6 weeks. * diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) criteria for brief psychotic disorder, schizophreniform disorder, schizophrenia, or schizoaffective disorder. exclusion criteria: * meeting dsm-iv criteria for drug dependence. * meeting dsm-iv criteria for mental retardation. * having a history of neurological disease or head injury.

Keywords: schizophrenia psychosis antipsychotics treatment response metabolic side effects gene expression rna genes
efficacy, safety, tolerability and pharmacokinetics (pk) of nilotinib (amn107) in pulmonary arterial hypertension (pah)

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this trial was to establish the safety, tolerability and pk of nilotinib in this population and to test the hypothesis that 6 months treatment with nilotinib will significantly reduce pulmonary artery resistance.

the purpose of this trial was to establish the safety, tolerability and pk of nilotinib in this population and to test the hypothesis that 6 months

Eligibility criteria:
inclusion criteria: * world health organization (who) functional class ii or iii * 6mwd ≥ 150 m and ≤ 450 m at screening * current diagnosis of pah according to dana point 2008 meeting * inadequate clinical response on one or more class(es) of pah drug * stabilization of pulmonary hypertension medications for ≥ 2 months on approved therapeutic dose of at least one pah drug and still symptomatic with who functional class ii or iii performance. exclusion criteria: * women of child-bearing potential not practicing birth control * in treatment with chronic nitric oxide therapy * pre-existing lung disease * use of drugs prolonging the qt interval or strong cyp3a4 inhibitors * long qt syndrome or qtc \> 450 ms males; \> 470 ms females. * who class iv * pulmonary capillary wedge pressure \> 15 mm hg * other diagnosis of pah in who diagnostic group 1 * pah associated with: venous hypertension (who diagnostic group ii), hypoxia (who diagnostic group iii), chronic pulmonary thromboembolic disease (who diagnostic group iv) or other miscellaneous causes (who diagnostic class v, which includes sarcoidosis, histiocytosis x, lymphangiomatosis, compression of pulmonary vessels) * thrombocytopenia \< 50 x109/l (50 x 103/µl) * uncontrolled systemic arterial hypertension, systolic \> 160 mm hg or diastolic \>90 mm hg * any advanced, severe, or unstable disease of any type that may interfere with the primary and secondary endpoint evaluations. other protocol-defined inclusion/exclusion criteria may apply

Keywords: pulmonary arterial hypertension nilotinib 6mwd pulmonary hypertension
anesthesia management of coronary artery bypass surgery and inflammatory biomarkers

Conditions: Coronary Artery Disease; Postoperative Complications; Anesthesia

Summary: the goal of this observational study is to evaluate effect of total intravenous anesthesia or inhalation anesthesia on inflammatory biomarkers in coronary artery bypass surgery and their relationship with early postoperative complications. the main questions it aims to answer are * does the type of anesthesia have a relationship with inflammatory biomarkers? * are inflammatory biomarkers associated with postoperative complications?

this study is planned to be a prospective observational clinical study. patients who will undergo on-pump coronary artery bypass surgery, meet the eligibility criteria and agree to participate in the study and sign the informed patient consent form will be included in the study.systemic immune inflammatory index, systemic inflammatory response index, neurophile lymphocyte ratio, platelet lymphocyte ratio will be calculated in the routine complete blood count of patients in the last 3 preoperative days and in the first 24 hours postoperatively.it will be evaluated whether these biomarkers are related to the anesthesia technique used, patients comorbidities and the complications that develop in the first 24 hours postoperatively. patients will be evaluated preoperatively, intraoperatively and postoperatively; preoperative comorbidities, intraoperative anesthesia management, cross clamp, pump and surgery times, blood and blood product transfusion, inotrope use and complications that develop up to the first 24 hours postoperatively will be recorded.the anesthetic technique to be used will be determined according to the anesthesiologist's preference and will be recorded.

Eligibility criteria:
inclusion criteria: * on-pump bypass surgery * del-nido cardioplegia used in operation * asa (american society of anesthesiologists) ii- iii patients exclusion criteria: * patients with active malignancy * diagnosed with systemic inflammatory disease or autoimmune disease * chronic liver and kidney disease * history of cerebrovascular disease within 6 months * ef (ejection fraction) \< 45% * non-cooperative or patients who do not agree to participate in the study
proprioception and eye-head coordination for the cervical spine

Conditions: Spinal Diseases

Summary: specific aims of this project were as follows: 1. to investigate the eye-head coordination of patients with cervical spine degeneration. 2. to investigate the relationship of these impairment measurements (range of motion, muscle power, proprioception, sensory threshold, eye-head coordination) and functional outcome (neck disability index, quality of life evaluation). 3. to develop a computer assistant device and software for the proprioceptive training and eye-head coordination. 4. to provide a treatment and prevention program emphasized on proprioception treatment and coordination for employee with neck-shoulder complaints.


Eligibility criteria:
inclusion criteria: * group one: participants without degenerated disease in cervical spine * group two: participants with degenerated disease in cervical spine exclusion criteria: * grade iii, iv degenerated cervical spine

Keywords: eye-head coordination proprioception cervical spine with degenerative disease degenerated cervical spine
improving care after chemotherapy

Conditions: Non-small Cell Lung Cancer; Colorectal Cancer; Breast Cancer

Summary: the main purpose of this study is to examine changes in patient-reported symptoms during the first two cycles of neoadjuvant or adjuvant chemotherapy for non-small cell lung cancer (nsclc), colorectal cancer (crc) and breast cancer, among patients who receive standard care plus a proactive nursing intervention relative to patients who receive standard care alone. interventions to improve symptom management and prevent urgent care needs in both the clinic and hospital for patients receiving chemotherapy with curative intent are needed to enhance the quality of cancer care.

* participants with nsclc, crc or breast cancer undergoing neoadjuvant or adjuvant chemotherapy will be asked to fill out self-report questionnaires at their first chemotherapy administration visit, in order to measure patient-reported symptoms, psychological distress, and satisfaction with oncology care. * participants will then be randomized into one of the two study groups: standard care with proactive phone calls from nurse practitioners or standard care alone. * participants assigned to the standard care group will be treated by their care team as would any other cancer patient. * participants assigned to the intervention group will receive four proactive phone calls from nurse practitioners designed to discuss symptom burden and management. proactive phone calls will occur 2-4 days after chemotherapy administration and 5-7 days after chemotherapy administration, during cycles 1 and 2. * participants will be asked to fill out the same set of questionnaires during their second and third chemotherapy administration visits, to assess patient-reported symptoms, psychological distress, and satisfaction with oncology care. * medical records will be reviewed at 24-weeks following the first chemotherapy administration visit, to evaluate frequency of urgent outpatient cancer center visits, emergency department visits, and hospital admissions that occurred during the study period.

Eligibility criteria:
inclusion criteria: * adult (age 18 or older) * newly diagnosed stage i-iii colorectal cancer, non-small-cell lung cancer, or breast cancer * scheduled to receive neoadjuvant chemotherapy (i.e. pre-surgical cancer-directed therapy with curative intent) or adjuvant chemotherapy (i.e. post-surgical cancer-directed therapy with curative intent) * able to respond to questions in english exclusion criteria: * already received 1 or more cycles of chemotherapy for the current regimen * unwilling or unable to participate in the study

Keywords: colonic neoplasms lung neoplasms patient-centered nursing breast neoplasms